Novo Nordisk, a leading pharmaceutical company, has announced that it will maintain the availability of its popular insulin brand, Mixtard, in vial form in India, despite the discontinuation of Penfill cartridges. This move comes in response to worries surrounding the withdrawal of commonly used insulin products. By streamlining its insulin offerings, the company aims to address the rising need from patients and guarantee a consistent medication supply, with a focus on innovative treatments. Novo Nordisk’s decision underscores its commitment to serving the Indian market with essential healthcare solutions.